Li responded, stating they used specific queries when using the TriNetX database, being sure to select patients with a history of stone disease prior to being started on GLP-1A use, then searching for subsequent new stone related events
The tirzepatide to semaglutide transition typically involves starting semaglutide at a moderate dose (0.5mg or 1.0mg weekly) rather than the standard 0.25mg starting dose, since the body is already adapted to GLP-1 receptor activation
Process Safety and Environmental Protection 199
You will be able to return to work and other normal activities immediately following treatment
If you suspect you have experienced an adverse reaction to a GLP-1 receptor agonist, including gallbladder problems, you can report this through the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or via the Yellow Card app)
Id be curious whether off-hours response times are as quick